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BACKGROUND: Percutaneous fine-needle aspiration (FNA) cytology is an important diagnostic test for the
evaluation and management of selected renal masses. Cytogenetic analysis of cytology specimens can
serve as an adjunct for precise classification because certain tumors are associated with specific chromo-
somal aberrations. This study summarizes our experience with the application of conventional cytogenetics
and fluorescence in situ hybridization (FISH) to renal FNA specimens. METHODS: All percutaneous renal
FNAs performed during 2005 through 2008 were identified from the electronic pathology database.
Results of cytogenetic and FISH analyses were correlated with the final diagnoses of the renal FNAs.
RESULTS: A total of 303 renal FNAs were performed. During an onsite assessment, a portion of the cytol-
ogy specimen was allocated for cytogenetic analysis in 74 cases. Karyotypic analysis or FISH was success-
ful in 44 (59%) of these. Characteristic chromosomal abnormalities were observed in 27 cases. In 17 cases,
a karyotype revealed a combination of trisomies/tetrasomies and in another 5 cases, FISH revealed trisomy
7 and 17, both of which are consistent with papillary renal cell carcinoma (RCC). Two cases showed 3p dele-
tions consistent with clear cell RCC. Trisomy 3 was observed in 1 case of clear cell RCC. Monosomy 1 and 17
was observed in a case of papillary RCC comprised oncocytic cells. In 1 case of primary renal synovial sar-
coma, FISH revealed a rearrangement at the SYT locus (18q11.2). CONCLUSIONS: Renal FNA specimens are
amenable to analysis by cytogenetics and FISH in the diagnosis and subclassification of renal neoplasms.
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Percutaneous biopsy serves as an important
diagnostic modality for the evaluation and manage-
ment of selected renal masses.1,2 Many renal mass biop-
sies are now performed using fine (19 gauge or thinner)
needles.2 Fine needles are generally considered safer
than larger needles and a diagnosis can be made based
on cytomorphology, especially in patients who are not
candidates for a nephrectomy. In a patient with a renal
mass undergoing cryoablation, radiofrequency abla-
tion, or ethanol injection, fine-needle aspiration (FNA)
may be the only opportunity to gain diagnostic insight
into the nature of the renal mass.3 Furthermore, a be-
nign diagnosis (eg, angiomyolipoma) can result in the
avoidance of unnecessary surgery. In patients who are
poor surgical candidates (eg, those with a solitary kid-
ney, a history of a prior nephrectomy, and a comorbid
condition), recognition of a good-prognosis subtype of
renal cell carcinoma (RCC; eg, papillary or chromo-
phobe) can help guide conservative therapy such as par-
tial nephrectomy or ablation. Thus, it is important to
diagnose renal masses on FNA as accurately as possible.
The accuracy of FNA alone in distinguishing benign
from malignant renal masses ranges from 73% to 94%.4
When renal cell carcinoma (RCC) is diagnosed, accurate
subclassification is achieved in 74% of cases.5 In some
cases, accurate diagnosis and assignment of the RCC sub-
type can be difficult; thus, adjuncts to routine cytomor-
phologic evaluation of renal FNA specimens have been a
topic of active investigation.
Renal tumors are frequently associated with clonal
cytogenetic abnormalities; thus, conventional cytogenetic
and FISH analyses could serve a crucial role in the diagno-
sis and subclassification of renal neoplasms, especially
RCC.6 Specifically, the clear cell, papillary, and chromo-
phobe variants of RCC are associated with 3p deletions, a
combination of trisomies, and a combination of monoso-
mies, respectively. Many studies that have investigated
cytogenetic abnormalities in renal tumors evaluated tissue
obtained from nephrectomy specimens. In contrast, there
are only a limited number of case reports and no series to
date in the literature that addresses the application of cyto-
genetics to renal FNAs. The aim of this report is to sum-
marize our experience in the application of karyotypic and
FISH analyses to FNAs of renal masses.
MATERIALS AND METHODS
After approval by the institutional review board, a search
of medical records for all percutaneous renal FNA proce-
dures performed at Brigham andWomen’s Hospital from
2005 through 2008 was conducted. A total of 303 FNAs
were performed during this time period; cytologic speci-
mens were obtained using fine (20-gauge, 23-gauge, and/
or 25-gauge) needles by a radiologist using imaging guid-
ance. Aspirated material was smeared onto glass slides.
Some smears were allowed to air dry and were stained
with the Hemacolor stain (Harleco, EM Science, Gibbs-
town, NJ). The remaining smears were fixed by direct
immersion in 95% ethanol or by spray-fixation with a
commercial isopropanol-based solution (Protocol Cyto-
logic Fixative; Fisher Scientific, Kalamazoo, Mich), fol-
lowed by staining with a modified Papanicolaou staining
procedure. The rapid evaluation of adequacy was per-
formed using the Hemacolor-stained smears, and 1 to 2
additional passes dedicated to the needle rinse were rec-
ommended when this was judged potentially useful, espe-
cially in cases where cytogenetics studies might have
added value. The fine needles were rinsed in RPMI media
and the needle-rinse specimen was apportioned for cyto-
genetics and/or preparation of cell blocks. For the latter,
the rinse was centrifuged at 1800 rpm for 10 minutes, the
pellet congealed with several drops each of plasma and
thrombin, and the resulting clot fixed in formalin and em-
bedded in paraffin for sectioning and staining with hema-
toxylin and eosin.
Cytology results were reported as ‘‘nondiagnostic’’ (ie,
insufficient or unsatisfactory for evaluation), ‘‘negative for
malignancy,’’ ‘‘atypical’’ (suggesting a low probability of
malignancy), ‘‘suspicious for malignancy’’ (suggesting a high
suspicion of malignancy), ‘‘neoplastic cells present,’’ or ‘‘posi-
tive for malignant cells.’’ These primary diagnostic categories
were supplemented by specific diagnoses when possible (eg,
angiomyolipoma, oncocytoma, and papillary RCC).
For cases in which a portion of the FNA had been
allocated for concurrent cytogenetic analysis during an
onsite adequacy assessment, the results of the conven-
tional cytogenetic and/or FISH analysis were correlated
with the cytologic interpretations and were not performed
in an independent, blinded fashion. Rather, the results of
cytogenetic/FISH testing were used to inform the final
cytologic interpretation whenever possible.
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GTG-banded karyotypes were obtained by cytoge-
netic technologists, according to standard procedures
using short term culture of fresh cells obtained from the
FNA7 and interpreted by a cytogeneticist. A chromosome
abnormality was considered clonal if it was present in at
least 2 metaphases (in the case of structural or numerical
abnormalities) or in at least 3 metaphases (in the case of
monosomies). If an abnormal karyotype was obtained, no
further FISH testing was performed. When karyotyping
was unsuccessful or a normal karyotype was obtained,
FISH analysis was performed when judged potentially
useful. Interphase FISH can be performed on fixed cell
suspensions prepared from uncultured FNA specimens or
using whole nuclei extracted from 50 micron sections pre-
pared from paraffin-embedded cell block preparations. In
our study, FISH was only performed on uncultured fixed
cell suspensions.
Fifty nuclei with discrete FISH signals were analyzed
using a 3-color centromeric probe set, according to the
manufacturer’s instructions (Abbott Molecular, Des
Plaines, Ill). The probe set included: D1Z1 (chromosome
1 alpha satellite DNA); D7Z1 (chromosome 7 alpha satel-
lite DNA), and D17Z1 (chromosome 17 alpha satellite
DNA). These probes were labeled with SpectrumOrange,
Spectrum Aqua, or Spectrum Green, respectively, and
were cohybridized. Although these centromeric probes are
not specifically designed to classify renal tumors, the com-
binatorial use of these 3 probes allows for papillary RCC
to be distinguished from chromophobe RCC. The ration-
ale for selecting this specific combination of probes is
because of several factors. First, because of the limited
availability of fluorochromes, a maximum of 3 differen-
tially labeled DNA probes can be cohybridized. Second,
the copy number of these 3 chromosomes varies in specific
ways between papillary and chromophobe RCCs. Papil-
lary RCC is most frequently associated with disomy 1,
trisomy/tetrasomy 7, and trisomy 17.8 In contrast, chro-
mophobe RCC typically shows monosomy 1, disomy 7,
and monosomy 17. Accordingly, observing 2 signals for
chromosome 1 and 2 signals for chromosome 7 in indi-
vidual nuclei from tumor cells serves as an internal control
for papillary and chromophobe RCC, respectively.
Hence, the use of the same 3 constituent probes can be
applied to both subtypes of tumors in a diagnostic setting.
To establish technical cutoffs, these 3 probes were hybri-
dized to nuclei obtained from clear cell RCCs with 3p-
demonstrated cytogenetically. As such, the clear cell RCC
specimens were used to establish a cutoff for hybridization
of this particular probe cocktail. The normal range for the
chromophobe-specific and papillary-specific patterns of
hybridization was from 0%-2% and 0%-4%, respectively.
However, in chromophobe RCC, it is important to be
aware that endoreduplication of chromosomes 1 and 17
in a population originally monosomic for both chromo-
somes will be result in disomy for each. This concomitant
finding has also been described cytogenetically.6 Finally,
the presence of a t(X;18)(p11;q11) translocation, a cyto-
genetic hallmark for synovial sarcoma, was evaluated
using the Vysis LSI SS18 Dual Color Break Apart Rear-
rangement probes, according to the manufacturer’s
instructions (Abbott Molecular, Des Plaines, Ill).
RESULTS
Of the 303 renal FNA specimens analyzed, aspirates with
cytologic interpretations of ‘‘nondiagnostic’’ and ‘‘atypi-
cal’’ were excluded as these were often acellular or pauci-
cellular specimens, leaving 198 FNA cases subject to
analysis in this study (Table 1). In 131 (66%) of 198, a
final interpretation of ‘‘positive for malignant cells’’ was
made. Of these, 121 were RCCs and 50, 36, and 9 of
them were subclassified as clear cell, papillary, and chro-
mophobe subtypes, respectively. Of the remaining 10 ma-
lignant cases, 7 cases were diagnosed as transitional cell
carcinoma, 1 as metastatic squamous cell carcinoma, 1 as
poorly differentiated carcinoma, and 1 as synovial sar-
coma. A final interpretation of ‘‘suspicious for malig-
nancy’’ was rendered in 27 (14%) of 198 cases, all of
which were suspicious for RCC. An interpretation of
‘‘neoplastic cells present’’ was made in 10 (5%) of 198
cases. In these 10 cases, the diagnosis of ‘‘oncocytic neo-
plasm’’ was rendered and it was not possible to precisely
classify the neoplasm as an oncocytoma, chromophobe
RCC, or other oncocytic neoplasm because of insufficient
material for ancillary studies. Finally, the interpretation,
‘‘negative for malignancy,’’ was made in 30 (15%) cases:
19 were diagnosed as oncocytoma; 9 as angiomyolipoma;
and 2 as metanephric adenoma.
During the on-site assessment, a portion of the nee-
dle rinse was allocated for cytogenetic analysis in 74
(37%) of the 198 cases. Conventional cytogenetics and/or
FISH analysis were successful in 44 (59%) cases (Table 2).
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A GTG-banded karyotype was obtained in 30 cases; chro-
mosome aberrations that correlated with specific RCC
subtypes were observed in 20 of these. Up to 20 meta-
phases (range, 3-20) were analyzed and diagnostic karyo-
typic abnormalities were seen in at least 3 metaphases
analyzed (range, 3-15) for each case. Normal or nonspe-
cific karyotypes were seen in the other 10 cases. Although
karyotypes could not be obtained in 44 cases, interphase
FISH analysis was performed in 14 of these cases and
chromosomal abnormalities were detected in 7 of them.
Fifty nuclei were counted in these cases and the diagnostic
abnormalities were seen in 4 (8%) to 46 (92%) of 50
nuclei.
Specific, abnormal karyotypic or FISH results were
seen in 27 cases (Table 3). In 26 of these 27 cases, the
results of the cytogenetic analysis were concordant with
the cytomorphologic impression of the renal tumor. Spe-
cifically, in 2 cases of clear cell RCC, karyotype analysis
revealed a deletion of 3p/-3, the cytogenetic hallmark of
clear cell RCC (Fig. 1). Trisomy 3, associated with clear
cell RCC,9 was observed in 1 case of clear cell RCC. A
combination of trisomies including those of chromo-
somes 7 and 17 was observed in 17 cases of papillary RCC
(Fig. 2). The presence of trisomy/tetrasomy 7 and trisomy
17 was demonstrated by FISH analysis in 5 additional
cases (Fig. 3). In 1 case, FISH analysis revealed the pres-
ence of a rearrangement involving 18q11.2 indicative of a
primary renal synovial sarcoma (Fig. 4). Evaluation of the
subsequent nephrectomy specimen confirmed a mono-
phasic synovial sarcoma.
Among the 27 cases exhibiting specific, abnormal
cytogenetic profiles, there was 1 case of RCC in which the
tumor exhibited papillary architecture and comprised cells
Table 1. Final Cytologic Interpretations of 198 FNA
Procedures
Interpretation/Diagnosis No.
Positive for malignant cells
Clear cell RCC 50
Papillary RCC 36
Chromophobe RCC 9
Consistent with RCC, NOS 26
Transitional cell carcinoma 7
Metastatic squamous cell carcinoma 1
Poorly differentiated carcinoma 1
Synovial sarcoma 1
Suspicious for malignancy








RCC indicates renal cell carcinoma; NOS, not otherwise specified.










FISH indicates fluorescence in situ hybridization.
Specific chromosomal abnormalities corresponding to certain types of re-
nal tumors observed via karyotypic analysis or interphase FISH (performed
when karyotyping was unsuccessful).
No chromosomal abnormalities observed by karyotypic analysis or inter-
phase FISH (performed when karyotyping was unsuccessful).
Karyotypic abnormalities were observed; however, the abnormalities were
not characteristic of any tumor. FISH was not subsequently performed in
these cases.
Karyotypic analysis was unsuccessful and FISH was not subsequently per-
formed in these cases.
Table 3. Common Cytogenetic Abnormalities in Different
Subtypes of Renal Tumors and Number of Tumors From
This Study That Exhibit These Abnormalities
Diagnosis/Cytogenetic Abnormality No. (%)
Clear cell RCC
3p deletion 2 (7)
Trisomy 3 1 (4)
Papillary RCC
Combination of trisomies or
tetrasomies (including
chromosomes 3, 7, 12, 16, 17, and 20)
17 (63)
Trisomy or tetrasomy 7 and trisomy 17a 5 (18)
Chromophobe RCC
Combination of monosomies
(including chromosomes 1, 2,
6, 10, 13, 17, and 21)
0 (0)
Monosomy 1 and 17a 1 (4)b
Translocation RCC
t(X;1) translocation 0 (0)
t(X;17) translocation 0 (0)
Synovial sarcoma
t(X:18) translocationa 1 (4)
Total 27 (100)
FISH indicates fluorescence in situ hybridization; RCC, renal cell
carcinoma.
Obtained by FISH.
In this case, the tumor comprised papillary clusters of oncocytic cells; the
diagnosis rendered on the follow-up partial nephrectomy specimen was
papillary RCC.
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with oncocytic cytoplasm (Fig. 5). Because a karyotype
could not be obtained, subsequent FISH was performed
and revealedmonosomies 1 and 17 and 2 copies of chromo-
some 7 raising the possibility of a chromophobe RCC (Fig.
5). A partial nephrectomy was subsequently performed and
the histopathologic diagnosis was papillary RCC of low
Figure 1. Fine-needle aspiration (FNA) and karyotypic analysis of a clear cell renal cell carcinoma (RCC) are depicted. (A) The
air-dried, Hemacolor-stained smear comprises tumor cells with vacuolated cytoplasm and associated with pink, strand-like mate-
rial. (B) Karyotypic analysis of metaphase chromosomes reveals a deletion of 3p through the loss of chromosome 3 (arrow).
Figure 2. Fine-needle aspiration (FNA) and karyotypic analysis of a papillary renal cell carcinoma (RCC) are depicted. (A) The
smear comprises tumor cells arranged in a papillary architecture. (B) The cell block preparation reveals delicate papillae charac-
teristic of a papillary RCC. (C) Karyotypic analysis revealed multiple trisomies involving chromosomes 3, 7, 12, 16, 17, and 20 along
with a loss of the Y chromosome (arrows).
Figure 3. Fine-needle aspiration (FNA) and fluorescence in situ hybridization (FISH) analysis of a papillary renal cell carcinoma
(RCC) are depicted. (A) The smear comprises papillary clusters of tumor cells associated with foamy macrophages, also
observed in the cell block (B). (C) FISH analysis of the tumor cells revealed trisomy 7 and 17.
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Fuhrman nuclear grade. Histologically, the tumor was com-
posed of oncocytic cells lining delicate papillae. Focally,
there were areas in which the papillary cores were filled with
foamy macrophages (Fig. 5). A Hale colloidal iron stain,
performed retrospectively on the cell block, was negative
(not shown), supporting the diagnosis.
DISCUSSION
Percutaneous biopsy is the only nonsurgical opportunity
to obtain a tissue diagnosis of renal masses. Because renal
masses are often biopsied with fine needles alone, render-
ing an accurate cytologic diagnosis is crucial and can pro-
vide important diagnostic information as to the benign or
malignant nature of the lesion. Furthermore, subtyping
malignant tumors can give insight into prognosis; for
example, chromophobe and papillary RCCs have been
associated with a better prognosis than other subtypes of
RCCs.10-14 Although some renal tumors can be accurately
subclassified based on morphologic grounds alone, others
can exhibit ambiguous morphologic features rendering
subtyping difficult, especially in small biopsies. Therefore,
the application of ancillary techniques such as immuno-
histochemistry and cytogenetics to the subclassification of
renal tumors has been a topic of active investigation.
Immunohistochemistry using a panel of markers
can be used in the diagnosis and subclassification of renal
tumors.15,16 This can be applied to smears, cell blocks,
and other preparations from FNAs. For instance, papil-
lary and chromophobe RCCs are generally immunoreac-
tive for cytokeratin 7 (CK7), oncocytomas exhibit
negative or focal, weak to moderate CK7 expression, and
clear cell RCCs are typically negative. Also, vimentin is
generally positive in clear cell and papillary RCCs and not
in chromophobe RCCs and oncocytomas. Furthermore,
alpha-methyl-coenzyme A racemase has been shown to
Figure 4. Fine-needle aspiration (FNA) and fluorescence in situ hybridization (FISH) analysis of a synovial sarcoma are depicted.
(A) The smear comprises delicate arrays of tumor cells with spindle-shaped hyperchromatic nuclei and scant cytoplasm. (B) The
cell block reveals sheets of small, blue, spindle cells similar to those seen in the smear. (C) FISH using a probe for the SYT locus
reveals evidence of a breakpoint and rearrangement at 18q11.2.
Figure 5. Fine-needle aspiration (FNA) and fluorescence in situ hybridization (FISH) analysis of a papillary renal cell carcinoma
(RCC) with oncocytic cells are depicted. (A) The aspirate comprises tumor cells with prominent papillary architecture. At the pe-
riphery of the papillae, the oncocytic cytoplasm of the tumor cells can be appreciated. (B) FISH analysis of the tumor cells
reveals monosomy 1 and 17. (C) In a section of the subsequently resected tumor, oncocytic cells lining delicate papillae can be
observed. Focally, foamy macrophages typical of papillary RCC can be identified.
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strongly highlight papillary RCCs while focally and
weakly staining approximately 25% of clear cell RCCs.16
Nonetheless, distinct subtypes of RCCs can occasionally
display overlapping immunoprofiles. Because cytogenet-
ics and FISH can reveal diagnostic chromosomal abnor-
malities specific to certain subtypes of renal tumors, these
molecular techniques can complement immunohisto-
chemistry in the subclassification of renal tumors, espe-
cially in cases that exhibit morphologic features that
overlap between different subtypes. As an illustration,
Gobbo et al used FISH in conjunction with immunohis-
tochemistry to accurately subtype RCCs with papillary
architecture and comprised of tumor cells with clear
cytoplasm.17
Conventional cytogenetics and FISH have revealed
characteristic chromosomal abnormalities in a variety of
renal tumors (Table 3).6 For instance, the conventional,
clear cell RCC is strongly associated with deletions on
chromosome 3p, which harbors tumor suppressor gene
loci including the Von Hippel-Lindau (VHL) gene.18-21
Loss of 3p can occur through simple interstitial or termi-
nal deletions, loss of chromosome 3, and unbalanced
translocations.22 The papillary subtype of RCC is typi-
cally associated with trisomy/tetrasomy 7, trisomy 17, and
the loss of the Y chromosome. The presence of only these
abnormalities has been associated with lack of metastatic
potential.8 Additional trisomies of chromosomes 3, 12,
16, and 20 can be present,23-25 and their presence has
been associated with increased propensity for local inva-
sion and metastasis.8 In contrast to papillary RCCs, chro-
mophobe RCCs are associated with low chromosome
number because of specific loss of the second copy of
chromosomes 1, 2, 6, 10, 13, 17, and 21.26,27 In this
regard, the detection of multiple monosomies by FISH
analysis can be helpful in accurately classifying oncocytic
neoplasms on FNA, especially in cases where the distinc-
tion of chromophobe RCCs from oncocytomas is difficult
because of overlapping cytomorphologic features and/or
equivocal results on immunohistochemistry. From a cyto-
genetic standpoint, oncocytoma can be classified into 3
groups: those with loss of chromosome 1 and/or 14 and 1
sex chromosome, most often the Y chromosome; those
with rearrangement of 11q13, with t(9;11) and t(5;11)
among the most frequent translocations observed; and
those with heterogeneous abnormalities, including both
numerical and structural aberrations.6 Finally, the Xp11.2
translocation RCC is recognized as a distinct entity in the
2004 World Health Organization classification of renal
tumors.28 The most common translocations are
t(X;1)(p11.2;q21) and t(X;17)(p11.2;q25) resulting in
fusions of the TFE3 gene on Xp11.2 with PRCC in 1q21
and ASPL in 17q25, respectively.29,30
In the studies investigating cytogenetic abnormalities
in renal tumors, surgically resected material typically repre-
sented the source of tumor tissue. To our knowledge, there
are no series, to date, that examined the application of cyto-
genetic analysis to fine-needle specimens, via karyotype anal-
ysis and/or FISH, in the diagnosis of renal neoplasms. There
are only a few case reports that have addressed the applica-
tion of cytogenetics/FISH techniques in material obtained
from renal FNA specimens. For example, Drut et al used
FISH for BCR to diagnose a renal rhabdoid tumor.31
We report our experience in interrogating the cyto-
genetic profiles of renal FNAs. For the cases in which a
portion of the FNA had been allocated for concurrent
cytogenetic analysis, the results of the karyotypic and
FISH analyses were not performed in an independent,
blinded fashion. The results of cytogenetic/FISH testing
were used to inform the final cytologic interpretation that
was released into the electronic medical record (listed in
Table 1). Because this study was a retrospective analysis of
final cytologic interpretations, it was not possible to deter-
mine and quantify the proportion of cases where the
results of cytogenetics and FISH resulted in subclassifying
cases of ‘‘RCC, NOS’’ or ‘‘suspicious for RCC.’’
Obtaining a karyotype has the advantage of providing
a more comprehensive view of chromosome aberrations,
such as translocations and chromosomal gains and losses,
compared with FISH interrogation of selected chromo-
somes or chromosomal regions. When the karyotype was
uninformative (ie, a normal karyotype or no karyotype was
obtained), we used FISH as target probes for centromeric
regions of chromosomes 1, 7 and 17 can be used to detect
chromosomal gains or losses allowing distinction between
papillary and chromophobe RCC, respectively. During the
course of this study, we did not use FISH probes to detect
high-frequency deletions in 3p for the diagnosis of clear cell
RCC. Beroukhim et al demonstrated that, although a vari-
ety of loci in 3p can be deleted in clear cell RCC, a signifi-
cant proportion of these tumors are associated with
deletions involving 3p25, which harbors the VHL gene
locus.32 Furthermore, FISH using cosmid and P1 probes
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that cover the VHL locus have been shown to detect most
deletions in VHL in families with VHL disease.33 Accord-
ingly, previous reports have illustrated that in some cases,
FISH using bacterial artificial chromosome or cosmid
probes can detect deletions in 3p to genetically establish a
diagnosis of clear cell RCC.34,35
In our series, karyotyping and/or FISH was successful
in 44 of the 74 cases where a portion of the FNAwas submit-
ted for cytogenetic analysis. Specific, abnormal cytogenetic
profiles were seen in 27 of these cases and the results were
concordant with the cytomorphologic impression of the re-
nal tumor except in 1 unusual case. In this renal FNA, the tu-
mor consisted of papillary clusters of oncocytic epithelial cells
with low-grade nuclei, and FISH analysis revealed 1 copy for
the centromeric regions of chromosomes 1 and 17. Although
this result was more indicative of chromophobe RCC, the
cytomorphologic features of the FNA and the morphology
of the tumor in the subsequent surgical resection specimen
were most consistent with a papillary RCC. A negative Hale
colloidal iron stain supported the diagnosis. As FISH inter-
rogates specific chromosomes, in this case chromosomes 1, 7,
and 17, the status of the remaining chromosomes were not
known. Furthermore, the discrepancy in the cytogenetic and
cytomorphologic findings could be reconciled in light of a
recent report by Lefevre et al describing karyotype deviations
of adult papillary renal cell carcinomas with oncocytic cells
compared with prototypical papillary RCCs.36 Specifically,
they reported losses of chromosomes 1, 14, and/or 15 in a
small number of these tumors.
In summary, our findings support the feasibility of
applying cytogenetics to fine-needle specimens in the di-
agnosis of renal tumors. On the basis of our experience,
conventional karyotypic analysis and FISH can reveal spe-
cific chromosomal abnormalities characteristic of com-
monly encountered renal tumors, especially clear cell and
papillary RCCs, as well as unexpected tumors including
synovial sarcomas.
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